April 18th 2024
Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
15th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 11, 2024
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
4th Annual International Congress on the Future of Women’s Health™
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Higher BMI in childhood may lead to higher risk of premenstrual disorders
March 29th 2022A higher childhood body mass index (BMI) was linked to a significantly greater risk of premenstrual disorders (PMDs) and premenstrual symptoms in young adulthood compared to children with normal BMI, according to a prospective cohort study in JAMA Network Open.
Read More
Tapping into the potential of combined laparoscopic salpingectomy and endometrial ablation
March 7th 2022Greg Marchand, MD, talks about his recently published article evaluating the underused potential of combined laparoscopic salpingectomy and endometrial ablation for treatment of abnormal uterine bleeding and desired sterilization.
Watch
How prevalent is PCOS in teen girls with type 2 diabetes?
February 28th 2022Polycystic ovary syndrome (PCOS) and type 2 diabetes have some markers that suggest a connection, with PCOS patients exhibiting certain symptoms at greater risk of developing type 2 diabetes later. A systematic review examines the prevalence of the 2 conditions occurring in adolescent girls.
Read More
Supporting transgender and gender-expansive individuals in reproductive health care
February 4th 2022At the Society for Maternal-Fetal Medicine’s 42nd Annual Meeting, a roundtable discussion explored ways to promote inclusivity and support transgender and gender-expansive individuals in the women’s health space.
Read More
Balancing the rewards and risks of hormonal acne treatments
January 31st 2022Julie Harper, MD, of the Dermatology and Skin Care Center of Birmingham, Alabama explained the use, side effects, and risks of spironolactone and oral contraceptives in a presentation at the current Maui Derm for Dermatologists meeting in Maui, Hawaii.
Read More
Poll: Will new technology bring a resurgence in enthusiasm for single port surgery?
January 5th 2022Much innovation has taken place in the field of minimally invasive gynecologic surgery in the last decade. Enthusiasm for single-port surgery has waned over the past decade, due to factors like Reimbursement issues and technical demand led to a decrease in enthusiasm, but robotics companies continue to develop new solutions.
Read More
Robotic surgery: A viable option for pectopexy
January 5th 2022While sacrocolpopexy has been the gold standard for the anatomical correction of pelvic organ prolapse for more than three decades, it is a technically challenging procedure that results in dividing the pelvis by mesh material and often requires extensive bowel manipulation.
Read More
Cytology dual-stain biomarker for detecting HPV-driven cervical precancer
December 27th 2021A prospective observational screening study has concluded a cytology dual-stain (DS) biomarker effectively triages women who test positive for primary human papillomavirus (HPV) and are at higher risk of developing cervical cancer, irrespective of the HPV genotype.
Read More
The addition of palbociclib to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
Read More
Type 2 diabetes risk not associated with gender-affirming hormone therapy, study shows
December 9th 2021A recent analysis suggests transfeminine individuals were at a 40% greater risk of developing diabetes than their cisgender counterparts, but this increase in risk was not attributable to gender-affirming hormone therapy.
Read More